Lidocaine   body {font-family: 'Open Sans', sans-serif;} .ui-header .ui-title, .ui-footer .ui-title { margin-right: 0 !important; margin-left: 0 !important; } \* { margin:0px; padding:0px;} .ui-page { background: #f2f2f2 url(bg.jpg); line-height:1.5em;} #home\_link { color:#FFF; text-decoration:none; cursor:pointer; font-family:'AndikaBasicRegular',Arial, sans-serif; font-size:0.9em; margin-left:15%; } #home\_link span {font-size:0.6em;margin-left:15%; color: #D8D8D8; } h1 {font-family:'AndikaBasicRegular'; }

# Lidocaine

**Lidocaine (Xylocaine)**  
**Class:** Class 1B anti-arrhythmic agent (membrane stabilizing and mild Na channels effects), and a local anesthetic (amide).  
It also blunts the gag reflex.  
**Do NOT give this drug when PVCs occur with bradycardia or escape rhythm.**  
Blunts dysrhythmias and tachycardia. Dose:1-1.5mg/kg IV  
Dosage should not exceed 300 mg/hr IV.  
**Onset:** 45-90 seconds  
**Half-Life:** Initial 7-30minutes, terminal 1.5-2 hours.  
**Elimination:** Hepatic  
**Decreases CBF, hypoxic drive, ICP and gag reflex:** Yes  
**Indications IV:** V Fib, VT, stable wide complex and ventricular ectopy, prophylaxis of arrhythmias associated with acute myocardial infarction and thrombolytic therapy.  
Precautions: CNS depressant, may cause seizures at high doses (although does have anticonvulsant properties).  
Can cause respiratory arrest.  
Also suppresses cough and gag reflexes.  
**Actions (IV):** Suppresses ventricular arrhythmias and elevates the fibrillation threshold (less likely to occur) by reducing velocity of electrical impulse through conductive system.  
**Actions (Local Anesthetic):** Blocks conduction of nerve impulses by decreasing permeability of Na on the nerve membrane (inhibiting conduction) thus depolarization blocking pain induction.  
**Complications:** CNS depression, seizures drowsiness, unconsciousness, apprehension, change in vision, vomiting, bradycardia, hypotension, seizures, AV block.  
Elderly patients more prone to listed complications.  
**Contraindications:**  
WPW  
SA/AV or intraventicular blocks with pacemaker.  
PVCs in conjunction with bradycardia.  
No longer recommended for VF/VT prophylaxis in acute MI. Suppresses ventricular arrhythmias and elevates the fibrillation threshold (less likely to occur).  
**Precautions:** Dosage should not exceed 300 mg/hr. Monitor for CNS toxicity. Dosage should be reduced by 50% in patients older than 70 years of age or who have liver disease in cardiac arrest, use only bolus therapy.  
**Side Effects:** Anxiety, drowsiness, dizziness, and confusion, nausea and vomiting, convulsions, widening of QRS,Tinnitus and metallic taste.

#### Copyright Â© 2012